Associations of retinoids, tamoxifen and α-interferon 2a in human breast cancer

In vitro and in vivo studies

Salvatore Toma, Patrizia Raffo, Laura Isnardi, Lucia Riccardi, Elena De Francisci, Giuseppina Maselli, Giuseppe Dastoli, Raffaella Palumbo

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We evaluated in vitro the potentiating and/or synergistic antitumor effects among retinoids (all-trans-retinoic acid, tRA, and 13-cis-retinoic acid, 13cRA), alpha-interferon 2a (α-IFN 2a) and tamoxifen (TAM) on both estrogen receptor positive (ER+) and negative (ER-) human breast cancer cell lines. In our experimental model, the three studied agents showed antiproliferative activity in ER+ cell lines MCF-7 and ZR-75.1, while α-IFN 2a was the most effective drug in the ER- cell line MDA-MB-231. Retinoids and TAM exerted a strong apoptotic effect in MCF-7 cells, while such an effect was obtained in MDA-MB-231 cells by α-IFN 2a. The tested combinations displayed different effects in the different evaluated cell lines: i) in MCF-7 cells tRA + TAM showed additive activity, both tRA + α-IFN 2a and TAM + α-IFN 2a association displayed a synergistic effect, and a further potentiation of the antiproliferative action was detected with the triple combination; ii) in ZR-75.1 cell line an additive activity was showed by tRA + TAM and TAM + α-IFN 2a, while tRA + α-IFN 2a produced synergistic action; iii) in MDA-MB-231 cell line only α-IFN 2a displayed a strong antiproliferative effect, and no significant potentiation was exerted by any drug association. The feasibility and activity of such combinations have been tested in two pilot clinical trials on patients with metastatic breast cancer: both the tested associations were tolerable, with good treatment compliance and low toxicity. The different antiproliferative and apoptotic effects observed in vitro on apparently similar breast cancer cell lines prompted us to a further investigation of the mutual biological modulations of these drug combinations, in view of a better selection of patients who might potentially benefit from these treatments.

Original languageEnglish
Pages (from-to)597-607
Number of pages11
JournalInternational Journal of Oncology
Volume10
Issue number3
Publication statusPublished - Mar 1997

Fingerprint

Retinoids
Tamoxifen
Interferons
Breast Neoplasms
Cell Line
MCF-7 Cells
Isotretinoin
Drug Combinations
Tretinoin
In Vitro Techniques
Estrogen Receptors
Pharmaceutical Preparations
Patient Selection
Theoretical Models
Clinical Trials
Therapeutics

Keywords

  • breast cancer
  • interferon
  • retinoids
  • tamoxifen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Associations of retinoids, tamoxifen and α-interferon 2a in human breast cancer : In vitro and in vivo studies. / Toma, Salvatore; Raffo, Patrizia; Isnardi, Laura; Riccardi, Lucia; De Francisci, Elena; Maselli, Giuseppina; Dastoli, Giuseppe; Palumbo, Raffaella.

In: International Journal of Oncology, Vol. 10, No. 3, 03.1997, p. 597-607.

Research output: Contribution to journalArticle

Toma, S, Raffo, P, Isnardi, L, Riccardi, L, De Francisci, E, Maselli, G, Dastoli, G & Palumbo, R 1997, 'Associations of retinoids, tamoxifen and α-interferon 2a in human breast cancer: In vitro and in vivo studies', International Journal of Oncology, vol. 10, no. 3, pp. 597-607.
Toma S, Raffo P, Isnardi L, Riccardi L, De Francisci E, Maselli G et al. Associations of retinoids, tamoxifen and α-interferon 2a in human breast cancer: In vitro and in vivo studies. International Journal of Oncology. 1997 Mar;10(3):597-607.
Toma, Salvatore ; Raffo, Patrizia ; Isnardi, Laura ; Riccardi, Lucia ; De Francisci, Elena ; Maselli, Giuseppina ; Dastoli, Giuseppe ; Palumbo, Raffaella. / Associations of retinoids, tamoxifen and α-interferon 2a in human breast cancer : In vitro and in vivo studies. In: International Journal of Oncology. 1997 ; Vol. 10, No. 3. pp. 597-607.
@article{180de2b74f944247a07016bc59789113,
title = "Associations of retinoids, tamoxifen and α-interferon 2a in human breast cancer: In vitro and in vivo studies",
abstract = "We evaluated in vitro the potentiating and/or synergistic antitumor effects among retinoids (all-trans-retinoic acid, tRA, and 13-cis-retinoic acid, 13cRA), alpha-interferon 2a (α-IFN 2a) and tamoxifen (TAM) on both estrogen receptor positive (ER+) and negative (ER-) human breast cancer cell lines. In our experimental model, the three studied agents showed antiproliferative activity in ER+ cell lines MCF-7 and ZR-75.1, while α-IFN 2a was the most effective drug in the ER- cell line MDA-MB-231. Retinoids and TAM exerted a strong apoptotic effect in MCF-7 cells, while such an effect was obtained in MDA-MB-231 cells by α-IFN 2a. The tested combinations displayed different effects in the different evaluated cell lines: i) in MCF-7 cells tRA + TAM showed additive activity, both tRA + α-IFN 2a and TAM + α-IFN 2a association displayed a synergistic effect, and a further potentiation of the antiproliferative action was detected with the triple combination; ii) in ZR-75.1 cell line an additive activity was showed by tRA + TAM and TAM + α-IFN 2a, while tRA + α-IFN 2a produced synergistic action; iii) in MDA-MB-231 cell line only α-IFN 2a displayed a strong antiproliferative effect, and no significant potentiation was exerted by any drug association. The feasibility and activity of such combinations have been tested in two pilot clinical trials on patients with metastatic breast cancer: both the tested associations were tolerable, with good treatment compliance and low toxicity. The different antiproliferative and apoptotic effects observed in vitro on apparently similar breast cancer cell lines prompted us to a further investigation of the mutual biological modulations of these drug combinations, in view of a better selection of patients who might potentially benefit from these treatments.",
keywords = "breast cancer, interferon, retinoids, tamoxifen",
author = "Salvatore Toma and Patrizia Raffo and Laura Isnardi and Lucia Riccardi and {De Francisci}, Elena and Giuseppina Maselli and Giuseppe Dastoli and Raffaella Palumbo",
year = "1997",
month = "3",
language = "English",
volume = "10",
pages = "597--607",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - Associations of retinoids, tamoxifen and α-interferon 2a in human breast cancer

T2 - In vitro and in vivo studies

AU - Toma, Salvatore

AU - Raffo, Patrizia

AU - Isnardi, Laura

AU - Riccardi, Lucia

AU - De Francisci, Elena

AU - Maselli, Giuseppina

AU - Dastoli, Giuseppe

AU - Palumbo, Raffaella

PY - 1997/3

Y1 - 1997/3

N2 - We evaluated in vitro the potentiating and/or synergistic antitumor effects among retinoids (all-trans-retinoic acid, tRA, and 13-cis-retinoic acid, 13cRA), alpha-interferon 2a (α-IFN 2a) and tamoxifen (TAM) on both estrogen receptor positive (ER+) and negative (ER-) human breast cancer cell lines. In our experimental model, the three studied agents showed antiproliferative activity in ER+ cell lines MCF-7 and ZR-75.1, while α-IFN 2a was the most effective drug in the ER- cell line MDA-MB-231. Retinoids and TAM exerted a strong apoptotic effect in MCF-7 cells, while such an effect was obtained in MDA-MB-231 cells by α-IFN 2a. The tested combinations displayed different effects in the different evaluated cell lines: i) in MCF-7 cells tRA + TAM showed additive activity, both tRA + α-IFN 2a and TAM + α-IFN 2a association displayed a synergistic effect, and a further potentiation of the antiproliferative action was detected with the triple combination; ii) in ZR-75.1 cell line an additive activity was showed by tRA + TAM and TAM + α-IFN 2a, while tRA + α-IFN 2a produced synergistic action; iii) in MDA-MB-231 cell line only α-IFN 2a displayed a strong antiproliferative effect, and no significant potentiation was exerted by any drug association. The feasibility and activity of such combinations have been tested in two pilot clinical trials on patients with metastatic breast cancer: both the tested associations were tolerable, with good treatment compliance and low toxicity. The different antiproliferative and apoptotic effects observed in vitro on apparently similar breast cancer cell lines prompted us to a further investigation of the mutual biological modulations of these drug combinations, in view of a better selection of patients who might potentially benefit from these treatments.

AB - We evaluated in vitro the potentiating and/or synergistic antitumor effects among retinoids (all-trans-retinoic acid, tRA, and 13-cis-retinoic acid, 13cRA), alpha-interferon 2a (α-IFN 2a) and tamoxifen (TAM) on both estrogen receptor positive (ER+) and negative (ER-) human breast cancer cell lines. In our experimental model, the three studied agents showed antiproliferative activity in ER+ cell lines MCF-7 and ZR-75.1, while α-IFN 2a was the most effective drug in the ER- cell line MDA-MB-231. Retinoids and TAM exerted a strong apoptotic effect in MCF-7 cells, while such an effect was obtained in MDA-MB-231 cells by α-IFN 2a. The tested combinations displayed different effects in the different evaluated cell lines: i) in MCF-7 cells tRA + TAM showed additive activity, both tRA + α-IFN 2a and TAM + α-IFN 2a association displayed a synergistic effect, and a further potentiation of the antiproliferative action was detected with the triple combination; ii) in ZR-75.1 cell line an additive activity was showed by tRA + TAM and TAM + α-IFN 2a, while tRA + α-IFN 2a produced synergistic action; iii) in MDA-MB-231 cell line only α-IFN 2a displayed a strong antiproliferative effect, and no significant potentiation was exerted by any drug association. The feasibility and activity of such combinations have been tested in two pilot clinical trials on patients with metastatic breast cancer: both the tested associations were tolerable, with good treatment compliance and low toxicity. The different antiproliferative and apoptotic effects observed in vitro on apparently similar breast cancer cell lines prompted us to a further investigation of the mutual biological modulations of these drug combinations, in view of a better selection of patients who might potentially benefit from these treatments.

KW - breast cancer

KW - interferon

KW - retinoids

KW - tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=0030978158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030978158&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 597

EP - 607

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 3

ER -